阿托伐他汀在急性冠脉综合征治疗中的应用

Effect of atorvastatin on acute coronary syndrome

目的:观察急性冠脉综合征((ACS)发生后应用不同剂量阿托伐他汀的疗效与安全性。方法:将84例ACS患者随机分成两组,分别给予阿托伐他汀治疗。治疗组阿托伐他汀80 mg/d,每晚1次,两周后改为20 mg/d;对照组阿托伐他汀20 mg/d,每晚1次。观察3个月两组患者血脂水平及心血管事件的发生率和药物不良反应。结果:两组治疗3个月后的总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高敏C反应蛋白(hs-CRP)水平显著降低,且治疗组优于对照组。结论:ACS患者早期强化降脂可减少心血管事件发生,治疗过程中无严重不良反应。

Objective： To observe the clinical therapeutic effect and safety of dose-respanse atorvastatin on acute coronary syndrome.Methods： A total of 84 cases of acute coronary syndrome were randomly divided into two groups.They were treated with atorvastatin.Atorvastatin administered subgroup were treated with atorvastatin（80 mg/d qN po） for 2 weeks,and then they were treated with atorvastatin（20 mg/d qN po）.At the same time,patients in observation group were treated with atorvastatin（20 mg/d,qN po）.After 3 months we compare level of blood lipid,cardiac events and safety of atorvastatin.Results： After 3 months tota1 cholestero1（TC）,low density 1ipoprotein cholestero1（LDL-C） and high-sensitivity C-reactive protein（hs-CRP） were significantly reduced in two groups.But the administered subgroup is more efficacious than observation group.Conclusion： Intensive lipid lowering is safe and effective in pantients of acute coronary syndrome.